Search Results - Richard E. Clark

  • Showing 1 - 14 results of 14
Refine Results
  1. 1
    c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia

    c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia by Claire M. Lucas, Robert J. Harris, Athina Giannoudis, Richard E. Clark

    Published 2015-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia

    Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia by Claire M. Lucas, Robert J. Harris, Athina Giannoudis, Elizabeth McDonald, Richard E. Clark

    Published 2014-11-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation

    Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation by Elena Karg, Christoph Baldow, Thomas Zerjatke, Richard E. Clark, Ingo Roeder, Ingo Roeder, Artur C. Fassoni, Ingmar Glauche

    Published 2022-12-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein

    Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein by Claire M. Lucas, Jemma L. Fagan, Anthony Carter, Bryony Swale, Craig Evans, Richard E. Clark, Robert J. Harris

    Published 2011-07-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia

    Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia by Ross Kinstrie, Dimitris Karamitros, Nicolas Goardon, Heather Morrison, Mike Hamblin, Lisa Robinson, Richard E. Clark, Mhairi Copland, Paresh Vyas

    Published 2016-12-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML

    CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell, Alison K. Holcroft, Robert K. Hills, Alan K. Burnett, Richard E. Clark

    Published 2018-05-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

    Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript by Claire M. Lucas, Robert J. Harris, Athina Giannoudis, Andrea Davies, Katy Knight, Sarah J. Watmough, Lihui Wang, Richard E. Clark

    Published 2009-10-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Serine 162, an essential residue for the mitochondrial localization, stability and anti-apoptotic function of Mcl-1.

    Serine 162, an essential residue for the mitochondrial localization, stability and anti-apoptotic function of Mcl-1. by Luke W Thomas, Connie Lam, Richard E Clark, Michael R H White, David G Spiller, Robert J Moots, Steven W Edwards

    Published 2012-01-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed

    Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed by Amr R. Ibrahim, Richard E. Clark, Tessa L. Holyoake, Jenny Byrne, Pat Shepherd, Jane F. Apperley, Dragana Milojkovic, Richard Szydlo, John Goldman, David Marin

    Published 2011-12-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial

    Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial by Nigel H. Russell, Robert K. Hills, Abin Thomas, Ian Thomas, Lars Kjeldsen, Mike Dennis, Charles Craddock, Sylvie Freeman, Richard E. Clark, Alan K. Burnett

    Published 2021-10-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation

    An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation by Paul Ferguson, Robert K. Hills, Angela Grech, Sophie Betteridge, Lars Kjeldsen, Michael Dennis, Paresh Vyas, Anthony H. Goldstone, Donald Milligan, Richard E. Clark, Nigel H. Russell, Charles Craddock

    Published 2016-11-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial

    Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial by Alan K Burnett, Emma Das Gupta, Steve Knapper, Asim Khwaja, Marion Sweeney, Lars Kjeldsen, Timothy Hawkins, Sophie E Betteridge, Paul Cahalin, Richard E Clark, Robert K Hills, Nigel H Russell

    Published 2018-10-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group

    Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group by Tapani Ruutu, Giovanni Barosi, Richard J. Benjamin, Richard E. Clark, James N. George, Alois Gratwohl, Ernst Holler, Massimo Iacobelli, Karim Kentouche, Bernhard Lämmle, Joel L. Moake, Paul Richardson, Gerard Socié, Zella Zeigler, Dietger Niederwieser, Tiziano Barbui

    Published 2007-01-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission

    Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in... by Bella Patel, Keiren E. Kirkland, Richard Szydlo, Rachel M. Pearce, Richard E. Clark, Charles Craddock, Effie Liakopoulou, Adele K. Fielding, Stephen Mackinnon, Eduardo Olavarria, Mike N. Potter, Nigel H. Russell, Bronwen E. Shaw, Gordon Cook, Anthony H. Goldstone, David I. Marks

    Published 2009-10-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: